— Know what they know.
Not Investment Advice

KROS Earnings

Keros Therapeutics, Inc.
1W: -2.2% 1M: +1.2% 3M: +3.0% YTD: -38.7% 1Y: -25.6% 3Y: -64.5% 5Y: -65.6%
$11.36
+0.10 (+0.89%)
 
Weekly Expected Move ±4.8%
$10 $11 $11 $12 $12
NASDAQ · Healthcare · Biotechnology · Tech Score Neutral · Power 54 · $225.2M mcap · 30M float · 0.783% daily turnover · Short 54% of daily vol
Last Earnings 2026-08-03
EPS
$-1.45
▼ Miss -8.2%
Revenue
$807K
Est (actual pending)
Next Earnings 2026-11-04
EPS Estimate
$-1.93
Range: $-2.22 - $-1.68
Revenue Estimate
$479K
4 analysts

Estimate vs Actual

Earnings Surprise History

11/19
EPS Beats
3/19
Revenue Beats
58%
EPS Beat Rate
16%
Rev Beat Rate

Wall Street Forward Estimates

Quarterly
Annual

Estimate Revisions

Recent Revisions
DatePeriodFiscal DateEPS OldEPS NewChangeRev OldRev New
2026-10-02 quarter 2026-09-30 $-0.94 $-0.94 — $14,764,286 $14,764,286
2026-10-02 quarter 2027-06-30 $-1.65 $-1.65 — $433,333 $433,333
2026-10-02 quarter 2027-09-30 $-1.75 $-1.75 — $433,333 $433,333
2026-10-02 annual 2026-12-31 $-5.54 $-5.54 — $15,562,143 $15,562,143
2026-10-02 quarter 2027-03-30 $-2.23 $-2.23 — $433,333 $433,333
2026-10-02 annual 2028-12-31 $-4.66 $-4.66 — $44,693,833 $44,693,833
2026-10-02 quarter 2026-12-30 $-1.93 $-1.93 — $478,571 $478,571
2026-10-02 annual 2027-12-31 $-6.24 $-6.24 — $13,725,987 $13,725,987
2026-10-02 quarter 2027-12-30 $-1.81 $-1.81 — $433,333 $433,333
2026-09-04 annual 2027-12-31 $-6.24 $-6.24 — $13,725,987 $13,725,987
2026-09-04 quarter 2027-12-30 $-1.81 $-1.81 — $433,333 $433,333
2026-09-04 quarter 2026-12-30 $-1.93 $-1.93 — $478,571 $478,571
2026-09-04 annual 2026-12-31 $-5.54 $-5.54 — $15,562,143 $15,562,143
2026-09-04 quarter 2027-09-30 $-1.75 $-1.75 — $433,333 $433,333
2026-09-04 quarter 2027-03-30 $-2.23 $-2.23 — $433,333 $433,333
Earnings Call Transcripts
No transcripts available.

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms